Usual prescribed care
Usual prescribed care within ECP; no study supplement.
01 / The question between visits
A prescription tells us what was intended. The pilot asks what happened next.
The intended medication schedule.
Actual injections, dates and doses.
Symptoms, intake and access barriers.
The physician’s decision and reason.
A more informative record for the next clinical conversation. A proposed pilot to test whether two practices can reliably produce it.
02 / The proposed comparison
One product and indication: prescribed Wegovy injection for chronic weight management.
Usual prescribed care within ECP; no study supplement.
The same care plus a proposed, protocol-defined DNA KEY® nutritional strategy informed by verified genetic results and measured patient characteristics.
The proposed comparison assigns participants equally by chance within each site. Both paths are proposed; neither is open.
DNA KEY® names the nutritional strategy. It does not edit DNA or determine medication dose. Its benefit is unknown.
The physician makes the prescribing decision independently of research participation. The study does not delay care.
03 / The proposed participant schedule
A short weekly account, brought together for a four-week clinical review.
Consent, starting measures
and genetic sample
Actual injections, symptoms
and missed-dose reasons
Medication reconciliation,
weight and clinician decision
Independent verification
of the endpoint record
Consent, clinical history, medication review, weight, genetic sample and agreed labs. The first actual injection—not the prescription date—anchors the medication timeline.
Record actual injection date and dose, missed doses and reasons, symptoms, intake and contact requests.
Reconcile medication use, record weight and document the clinician’s decision at weeks 4, 8, 12, 16, 20 and 24. Labs are planned at baseline, week 12 and week 24.
Independently verify the week-24 endpoint record. With permission, follow-up can continue even when medication stops.
Labs: baseline · week 12 · week 24. A wearable is optional.
04 / From observations to documentation
Confirm the independent prescribing decision, eligibility and consent.
Establish the starting point
Collect clinical measures, genetic results and patient reports. Distinguish the prescribed schedule from actual injections.
Intended is not actual
Align dates and units, preserve original observations and flag gaps or mismatches. No report is not the same as no symptom.
Keep gaps visible
The clinician reviews routine packets, records a decision and reason, and documents study-product use separately. Urgent symptoms go directly to the clinic’s urgent contact route, not the routine research queue.
Decision + reason
Check record integrity over time and independently verify week-24 measurements and medication exposure.
Check against the record
Illustrative record — not patient data
One injection scheduled this week.
No injection recorded for the scheduled date.
Reason and source documented below.
Clinician decision, reason and signature recorded separately.
Recorded reason: Access delay. Patient reports that medication was unavailable.
Documentation: patient report date, access barrier and unresolved exposure information retained for review. This records access, not an assumption about adherence.
Recorded reason: Symptoms reported. Patient reports symptoms as the reason for the missed injection.
Documentation: report date, symptom timing and patient account retained. Missing details stay flagged; the record does not infer cause or a treatment decision.
Recorded reason: Clinician-directed hold. A clinician’s documented instruction explains the missing injection.
Documentation: instruction date, clinician source and stated reason retained. A clinician-directed hold is not patient nonadherence.
Urgent symptoms go directly to the clinic’s urgent contact route—not into the routine research queue. The examples document reasons; they do not provide treatment advice.
05 / The primary feasibility question
Proposed target · 80%
At least 48 of 60 complete week-24 records.
A complete record: verified baseline and week-24 weight (week 24 ±7 days), reconciled medication exposure and a signed clinician decision.
The denominator: all randomized participants, including those who discontinue medication.
Can the team see actual exposure, symptoms, access issues and missing information together? How much review time does that take?
Can a short check-in capture what happened and why, including when a dose was missed?
Can both sites complete comparable records? Do genetics add information beyond clinical measures? Is the nutritional strategy practical enough to study further?
Weight change, symptom burden and persistence are exploratory measures—not the primary feasibility target. Both paths use ECP, so this comparison cannot establish that ECP itself improves outcomes versus no ECP. Improved care and reduced workload are not established results.
06 / The decision for a participating practice
Three discussion items for a physician-led collaboration.
Proposed next step: protocol development with two prescribing practices.This is not a request to recruit patients or begin study treatment.